News

BlockBeats News, June 5th, JPMorgan Chase announced that it has raised its price target for a company from $160 to $265. According to Bitget market data, the pre-market trading price of the company dropped by 2.05% to $237.6.

Glonghui, June 5 ｜ According to a report released by BofA Securities, Broadcom's second-quarter results and third-quarter outlook were only slightly above market expectations. However, the bank emphasized that significant absolute AI growth remains on track for a year-over-year increase of approximately 180% in fiscal year 2026 and nearly 100% growth in fiscal year 2027. Management did not raise the previously stated AI revenue target of around $100 billion for fiscal year 2027, despite high market expectations (considering the robust TPU growth momentum), which the bank believes reflects a conservative stance due to ongoing client-side supply constraints. Meanwhile, several new custom XPU clients (Anthropic, Meta, OpenAI, as well as two others) are expected to gradually ramp up volumes over the coming quarters, potentially adding momentum to the strong foundation of Google TPU. Robust software growth in the third quarter (over 30% year-on-year) also demonstrates multiple growth vectors within the AI theme. The bank continues to expect annual earnings per share to exceed $30 by 2030, with an annualized earnings per share compound growth rate of about 40% between 2025 and 2030. BofA Securities reiterated its “Buy” rating on Broadcom, raised its fiscal 2026 to 2028 revenue and earnings per share forecasts by 2% to 6%, and increased the target price from $450 to $530.

Glonghui, June 5｜Biogen (BIIB.US) rose 3.8% pre-market to $204. According to reports, Biogen announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to salanersen for the treatment of spinal muscular atrophy (SMA). The breakthrough therapy designation aims to accelerate the development and review process of drugs for serious diseases, provided that preliminary clinical evidence indicates the drug may demonstrate substantial improvement over existing therapies on clinically significant endpoints. Salanersen is a novel antisense oligonucleotide (ASO) under development and is expected to deliver highly effective results in SMA treatment with an annual dosing regimen.